District court denies another Amgen motion in biosimilars case

The U.S. District Court for the Northern District of California denied a motion from Amgen Inc. (NASDAQ:AMGN) for a preliminary injunction pending appeal that would delay the launch of Zarxio filgrastim-sndz from the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). The biosimilar of Amgen's Neupogen filgrastim is the first approved biosimilar product in the U.S.

Amgen had argued last month that it would suffer irreparable harm from "immediate and irreversible price erosion" if Sandoz launched Zarxio during Amgen's appeal of the district court's ruling. In its denial Wednesday, the district court said Amgen's argument appears "speculative" and "does not merit injunctive relief." ...